Antiparkinson Agents/therapeutic use; Dopamine Agonists/therapeutic use; Parkinson Disease/drug therapy; Tetrahydronaphthalenes/therapeutic use; Thiophenes/therapeutic use; Administration, Cutaneous; Adult; Aged; Antiparkinson Agents/administration & dosage; Antiparkinson Agents/adverse effects; Antiparkinson Agents/economics; Canada; Dopamine Agonists/administration & dosage; Dopamine Agonists/adverse effects; Dopamine Agonists/economics; Drug Approval; Humans; Middle Aged; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes/administration & dosage; Tetrahydronaphthalenes/adverse effects; Tetrahydronaphthalenes/economics; Thiophenes/administration & dosage; Thiophenes/adverse effects; Thiophenes/economics; Treatment Outcome; United States; United States Food and Drug Administration